Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipo-PGE1
- Development stage
- Unknown
- Lead developer
- Tongji Hospital
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Lipo-PGE1 is a lipid microsphere formulation of alprostadil (prostaglandin E1), a potent vasodilator and inhibitor of platelet aggregation. The lipid emulsion technology encapsulates the active ingredient, protecting it from rapid inactivation by pulmonary enzymes and allowing for targeted delivery to damaged vascular endothelial cells. This formulation is designed to improve microcirculation and reduce peripheral vascular resistance. In clinical research led by Tongji Hospital, Lipo-PGE1 is being evaluated for its ability to improve coronary microvascular perfusion and address coronary microvascular dysfunction in patients suffering from ischemic heart disease, particularly those with comorbid type 2 diabetes mellitus.
- Other names
- Alprostadil lipid emulsionLipo-prostaglandin E1Prostaglandin E1 lipid microsphereLiposomal alprostadil
02
Targets
PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER (Prostaglandin E2 receptor)
Beyond the preview
Go deeper on Lipo-PGE1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipo-PGE1.